Chronic kidney disease (CKD) is a progressive condition in which the kidneys gradually lose their ability to filter waste and excess fluids from the blood. Often described as a “silent killer,” CKD usually shows no noticeable symptoms in its early stages. By the time warning signs appear, many patients already have irreversible kidney damage and may require dialysis to manage the disease.
In the Philippines, CKD cases rose to 35.94 percent in 2022, significantly higher than the global average of 9.1 to 13.4 percent. People with hypertension and Type 2 diabetes are the most at risk, with one in three affected. These figures underscore the need for early testing and awareness to allow timely detection and intervention.
One of the most effective tools for early detection is the Urine Albumin-to-Creatinine Ratio (UACR) test, which measures the presence of albumin, a protein, in the urine. Healthy kidneys keep essential protein in the bloodstream, while damaged kidneys allow it to leak into the urine. Detecting even trace amounts of albumin can signal early kidney stress before symptoms appear. In hospitals, UACR testing typically costs between P2,000 and P3,500.
To encourage Filipinos to take proactive steps toward kidney health, Mercury Drug Inc., in partnership with AstraZeneca Philippines and Diabetes Philippines, is offering free UACR testing at four selected Mercury Drug branches: EDSA Pavilion and EDSA Shangri-La Plaza in Mandaluyong City, Trinoma Mall in Quezon City, and Noveleta Magdiwang in Cavite. The tests are available year-round, from Wednesdays to Sundays, during each branch’s operating hours.
